AI Cancer-Risk Tool Used by UK’s NHS Under FDA Review, U.S. Launch Targeted for 2027

C the Signs, a medical device that scans patient records to flag cancer risk, is under review by the Food and Drug Administration, its developer told Newsweek. The company plans to make the tool available to Americans in 2027 if cleared. It is already deployed across the United Kingdom’s National Health Service, where more than 11,000 clinicians use it and 75,000 patients with cancer have been identified.

Dr. Bea Bakshi, co-founder and chief executive of C the Signs, said the FDA informed the company it had not previously seen a comparable product, allowing C the Signs to pursue De Novo classification for a novel low-to-moderate-risk device. While the application is pending, the company intends to provide the tool to 250,000 Americans this year as part of a study, Bakshi said.

The device analyzes existing medical records in under 60 seconds without requiring new tests or imaging. C the Signs maintains separate models for each cancer type. It reports a 99 percent negative predictive value for detecting cancer and 94 percent accuracy in predicting tumor origin.

U.K. Bakshi said cancer screening programs in both countries cover only a small number of more than 200 cancer types, leaving many patients on a “convoluted journey” that can involve multiple appointments before diagnosis. A Mayo Clinic study reviewed records of one million patients in Arizona, Minnesota and Florida.

It found that one in four patients could be identified between 12 months and five years earlier than their eventual physician diagnosis when C the Signs was applied. U.S. Multipayer system. He recommended starting with early adopters to demonstrate value before seeking Medicare and Medicaid coverage, while also pursuing direct-to-consumer marketing.

U.S. Populations is essential because demographics, documentation practices and care pathways differ from NHS settings. David Walt, professor of biologically inspired engineering at Harvard Medical School, noted that other AI systems use similar methods.

He questioned whether continuous risk updates are the best approach, citing the likelihood of false positives and resulting psychological stress for patients.

The company supplied Newsweek with patient and clinician testimonials praising faster diagnosis. C the Signs states that around one in two people are missed at their first medical appointment when cancer risk is present.